XtalPi AI-Designed PEP08 PRMT5 Inhibitor Approved for Phase I
September 10, 2025 | 16:09
Algorithm-to-clinic success slashes discovery time 30%—Taiwan FDA green-lights first-in-human trials targeting rare solid tumors.
XtalPi, Dong-A ST Ink R&D Pact on Immunology Therapies
August 20, 2025 | 18:15
Partnership will focus on new treatments for immune and inflammatory diseases.
XtalPi partners with DoveTree to develop novel AI-powered therapeutics
June 23, 2025 | 10:00
The collaboration aims to revolutionize drug discovery through AI and robotics, guided by renowned Harvard Professor Gregory Verdine.
Mobile Version